Insights From Survival Analyses During 12 Years of Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Insights From Survival Analyses During 12 Years of Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

Published:2021-01-01 Issue:1 Volume:139 Page:57
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Fu Dun Jack¹²,Keenan Tiarnan D.³,Faes Livia¹²⁴,Lim Ernest¹²,Wagner Siegfried K.¹²,Moraes Gabriella¹²,Huemer Josef¹²⁵,Kern Christoph¹²⁶,Patel Praveen J.¹²,Balaskas Konstantinos¹²,Sim Dawn A.¹²⁷,Bunce Catey⁸,Stratton Irene⁹,Keane Pearse A.¹²⁷

Affiliation:

1. Moorfields Eye Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom

2. University College London Institute of Ophthalmology, London, United Kingdom

3. Department of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland

4. Eye Clinic of the Cantonal Hospital of Lucerne, Lucerne, Switzerland

5. Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna, Austria

6. Department of Ophthalmology, University Hospital of Munich, Munich, Germany

7. School of Population Health and Environmental Sciences, King’s College London, London, United Kingdom

8. Gloucestershire Retinal Research Group, Gloucester, United Kingdom

9. National Institute for Health and Research Biomedical Center, Moorfields Eye Hospital, London, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2772986/jamaophthalmology_fu_2020_oi_200091_1610718707.7998.pdf

Reference54 articles.

1. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.;Wong;Lancet Glob Health,2014

2. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group.;Spaide;Ophthalmology,2020

3. The role of inflammation in the pathogenesis of age-related macular degeneration.;Donoso;Surv Ophthalmol,2006

4. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.;Heier;Ophthalmology,2012

5. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial.;Gillies;JAMA Ophthalmol,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inter-Reader and Inter-Modality Variability in Macular Atrophy Quantification in Neovascular AMD: Comparison of Six Imaging Modalities.;Ophthalmology Retina;2024-08

2. Long-term results of treatment of neovascular age-related macular degeneration using antiangiogenic drugs: A review of the literature;Archivos de la Sociedad Española de Oftalmología (English Edition);2024-05

3. Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy;Clinical Pharmacology & Therapeutics;2024-03-07

4. LONG-TERM USE OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2024-02

5. Resultados a largo plazo del tratamiento de la degeneración macular asociada a la edad neovascular mediante fármacos antiangiogénicos: revisión de la bibliografía;Archivos de la Sociedad Española de Oftalmología;2023-12